GlassScriptPhysician profile
Josh D Gast
NPI 1437404761
$1,115.69
in general payments reported to CMS, 2019-2025
26 companies · $355 in 2025
The $355 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.96 · 2020: $155 · 2021: $50.56 · 2022: $53.81 · 2023: $240 · 2024: $239 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $833.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $139.88 | 2023-2025 | Spravato, Invega Sustenna |
| Abbvie INC. | $126.45 | 2020-2024 | |
| Alkermes, INC. | $92.21 | 2025 | Aristada, Vivitrol, Lybalvi |
| Lilly USA, LLC | $80.14 | 2020-2025 | Olumiant, Taltz, Mounjaro |
| Amgen INC. | $72.87 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $69.45 | 2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.63 | 2023-2024 | Xifaxan |
| Lundbeck LLC | $42.53 | 2024 | Rexulti |
| Braeburn INC. | $41.68 | 2025 | Brixadi |
| Leo Pharma INC. | $40.05 | 2020 | |
| Abbott Laboratories | $39.78 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.50 | 2024 | Caplyta |
| Biofrontera INC. | $37.07 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Novo Nordisk INC | $28.33 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Ironshore Pharmaceuticals INC. | $27.53 | 2023 | Jornay Pm |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $23.89 | 2025 | Gemtesa |
| Viatris Specialty LLC | $22.72 | 2025 | Yupelri |
| Grifols USA, LLC | $22.20 | 2023 | Prolastin-C Liquid |
| Janssen Biotech, INC. | $20.73 | 2023 | Tremfya |
| Ucb, INC. | $19.17 | 2020 | |
| Exact Sciences Corporation | $17.88 | 2025 | Cologuard Collection Kit |
| Averitas Pharma INC. | $16.10 | 2024 | Qutenza |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.03 | 2022 | |
| Vanda Pharmaceuticals INC. | $13.89 | 2025 | Fanapt |
| Kowa Pharmaceuticals America, INC. | $13.72 | 2021 | |
| Apria Healthcare LLC | $13.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josh Gast listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.